trending Market Intelligence /marketintelligence/en/news-insights/trending/QVvApuP1NRoeDgqu53oYCQ2 content esgSubNav
In This List

Mylan settles litigation with Apotex, discloses subpoena from DOJ


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Mylan settles litigation with Apotex, discloses subpoena from DOJ

Mylan NV settled another antitrust lawsuit that alleged the company delayed the launch of a generic version of Cephalon Inc.'s modafinil in exchange for payments.

Mylan reached an undisclosed agreement with Apotex Inc. who had made the claims. The agreement is separate from the $96.5 million Mylan will pay to direct drug buyers for the same allegations.

Modafinil, also known as Provigil, is a sleep disorder drug.

In separate news, the U.S. Department of Justice subpoenaed Mylan, seeking information related to its opioid products.

The request comes after U.S. Sen. Claire McCaskill, D-Mo., launched an investigation into the top five prescription opioid makers, including Mylan, for possible contribution toward the opioid epidemic.

McCaskill, who had written to Mylan seeking information regarding its opioid products, had also requested the DOJ to conduct an internal investigation into the ability of the Drug Enforcement Agency to hold major drug distributors accountable for opioid diversion.

Meanwhile, the Department of Veterans Affairs is considering whether Mylan's allergy injector EpiPen should be covered under the section 603 of the Veterans Health Care Act, making it eligible for a discount.

U.S. government investigators say the company may have overcharged Medicaid by as much as $1.27 billion over a decade by incorrectly classifying EpiPen as a generic drug rather than a brand-name medicine.